复方守宫散对TP方案治疗的晚期非小细胞肺癌患者血液学毒性及免疫功能的影响

目的 观察复方守宫散对晚期非小细胞肺癌（non small cell lung cancer，NSCLC）化疗患者血液毒性及免疫功能的影响。方法 将62例晚期肺癌患者随机分为治疗组和对照组，每组31例，对照组予以TP（紫杉醇+顺铂）方案化疗，治疗组予以复方守宫散联合TP方案治疗。观察两组患者近期疗效、血液毒性，比较两组治疗前后免疫功能及生存质量。结果 两组患者WBC、HGB减少分级比较，差异有统计学意义（P＜0.05），PLT分级比较差异无统计学意义（P＞0.05）。与治疗前比较，TP方案治疗后对照组CD3+、CD4+、CD8+ T细胞绝对值及CD4+/CD8+比值均显著下降（P＜0.05），治疗组CD3+、CD4+ T细胞绝对值均显著下降（P＜0.05），CD8+ T细胞绝对值及CD4+/CD8+比值变化不明显（P＞0.05）；治疗组治疗前后CD3+、CD4+、CD8+ T细胞绝对值及CD4+/CD8+比值的差值均明显小于对照组，差异有统计学意义（P＜0.05）。两组近期疗效分布比较，差异无统计学意义（P＞0.05）。两组患者生存质量分布比较，差异有统计学意义（P＜0.05）。结论 复方守宫散可以改善晚期肺癌患者免疫功能，减轻化疗的血液学毒性及提高生存质量。

Effect of Compound Shougong Powder on Hematological Toxicity and Immune Function in Patients with Advanced Non-small Cell Lung Cancer Treated with TP Regimen

Objective To investigate the effect of Compound Shougong Powder on hematological toxicity and immune function in patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.Methods A total of 62 patients with advanced NSCLC were randomly divided into treatment group and control group, with 31 patients in each group. The patients in the control group received paclitaxel+cisplatin (TP) chemotherapy, and those in the treatment group were given Compound Shougong Powder combined with TP chemotherapy. The two groups were compared in terms of short-term response, hematological toxicity, immune function before and after treatment, and quality of life. Results There were significant differences in the reductions in white blood cell count and hemoglobin between the two groups (P<0.05), while there was no significant difference in the reduction in platelet count between the two groups (P>0.05). After treatment, the control group had significant reductions in the absolute counts of CD3+, CD4+, and CD8+ T cells and CD4+/CD8+ ratio (P<0.05), and the treatment group had significant reductions in the absolute counts of CD3+ and CD4+ T cells (P<0.05), without significant changes in the absolute count of CD8+ T cells and CD4+/CD8+ ratio (P>0.05); the control group had significantly greater reductions in the absolute counts of CD3+, CD4+, and CD8+ T cells and CD4+/CD8+ ratio compared with the treatment group (P<0.05). There was no significant difference in the distribution of short-term outcomes between the two groups (P>0.05). There was a significant difference in the distribution of quality of life between the two groups (P<0.05). Conclusion In patients with advanced NSCLC, Compound Shougong Powder can enhance their immune function, alleviate the hematological toxicity of chemotherapy, and improve quality of life.